Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranylcypromine + Tretinoin in Relapsed/Refractory AML and MDS
NCT02273102Phase 1Completed
- Sponsor
- University of Miami
- Start
- Mar 2015
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tranylcypromine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by University of Miami. Primary endpoint: Rate of Toxicity in Study Participants Receiving TCP/ATRA Combination Therapy at 24 months. Started Mar 2015; status: completed.
02
Drugs
tranylcypromine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02273102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273102.